ArticleVaccine2015
Competitive detection of influenza neutralizing antibodies using a novel bivalent fluorescence-based microneutralization assay (BiFMA).
Article in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- MF59-adjuvanted A/Astrakhan influenza vaccine induces cross-neutralizing H5N1 antibodies in ferrets against circulating clade 2.3.4.4b viruses.NPJ vaccines · 2026Article
- Evolution of the PRNT: Merging tradition and innovation to set the gold standard in the era of automation.Human vaccines & immunotherapeutics · 2025Review
- Observational
- Recombinant Influenza A Viruses Expressing Reporter Genes from the Viral NS Segment.International journal of molecular sciences · 2024Review
- Outlining recent updates on influenza therapeutics and vaccines: A comprehensive review.Vaccine: X · 2024Review
- Highly Cross-Reactive and Protective Influenza A Virus H3N2 Hemagglutinin- and Neuraminidase-Specific Human Monoclonal Antibodies.Microbiology spectrum · 2023Article
- Generation and Characterization of Single-Cycle Infectious Canine Influenza A Virus (sciCIV) and Its Use as Vaccine Platform.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Rapid Assessment of Neutralizing Antibodies Using Influenza Viruses with a Luciferase Reporter.Applied biochemistry and microbiology · 2022Article
- Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2.iScience · 2021Article
- A New Master Donor Virus for the Development of Live-Attenuated Influenza B Virus Vaccines.Viruses · 2021Article
- Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.Journal of virological methods · 2021Article
- Host Single Nucleotide Polymorphisms Modulating Influenza A Virus Disease in Humans.Pathogens (Basel, Switzerland) · 2019Review
- A Novel Fluorescent and Bioluminescent Bireporter Influenza A Virus To Evaluate Viral Infections.Journal of virology · 2019Article
- Article
- Review
- Recent Advances in AIV Biosensors Composed of Nanobio Hybrid Material.Micromachines · 2018Review
- Antigenicity of the 2015-2016 seasonal H1N1 human influenza virus HA and NA proteins.PloS one · 2017Article
- Fluorescent and Bioluminescent Reporter Myxoviruses.Viruses · 2016Review
- Development and applications of single-cycle infectious influenza A virus (sciIAV).Virus research · 2016Review
- Replication-competent fluorescent-expressing influenza B virus.Virus research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Avian-derived influenza A zoonoses are closely monitored and may be an indication of virus strains with pandemic potential. Both successful vaccination and convalescence of influenza A virus in humans typically results in the induction of antibodies that can neutralize viral infection. To improve long-standing and new-generation methodologies for detection of neutralizing antibodies, we have employed a novel reporter-based approach that allows for multiple antigenic testing within a single sample. Central to this approach is a single-cycle infectious influenza A virus (sciIAV), where a functional hemagglutinin (HA) gene was changed to encode either the green or the monomeric red fluorescent protein (GFP and mRFP, respectively) and HA is complemented in trans by stable HA-expressing cell lines. By using fluorescent proteins with non-overlapping emission spectra, this novel bivalent fluorescence-based microneutralization assay (BiFMA) can be used to detect neutralizing antibodies against two distinct influenza isolates in a single reaction, doubling the speed of experimentation while halving the amount of sera required. Moreover, this approach can be used for the rapid identification of influenza broadly neutralizing antibodies. Importantly, this novel BiFMA can be used for any given influenza HA-pseudotyped virus under BSL-2 facilities, including highly pathogenic influenza HA isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.